Poonnoose Santosh Isaac, Rajshekhar Vedantam
Department of Neurological Sciences, Christian Medical College and Hospital, Vellore, India.
Neurosurgery. 2003 Oct;53(4):873-8; discussion 878-9. doi: 10.1227/01.neu.0000083553.25421.6f.
The goal of this study was to determine the rate of radiological resolution of histopathologically proven tuberculomas treated with antituberculous therapy (ATT). The effects of the size of the tuberculomas, the number of tuberculomas, and the addition of corticosteroid therapy on the rate of resolution of the tuberculomas were also studied.
Twenty-eight patients (age range, 5-48 yr; 14 male and 14 female patients) with histologically proven intracranial tuberculomas were prospectively monitored with contrast-enhanced computed tomographic scans. The patients received ATT consisting of rifampicin and isoniazid for a period of 18 months, with ethambutol and/or pyrazinamide for a minimum of 3 months. Fifteen patients also received corticosteroid therapy for 1 to 6 weeks. Of the 28 patients, 17 patients underwent partial excision, 6 underwent open biopsy, and 5 underwent stereotactic biopsy of their tuberculomas.
Kaplan-Meier analysis revealed that, after 9 months of ATT, only 18.2% of the patients demonstrated complete resolution of their tuberculomas; even after 18 months of ATT, 69.2% of the patients had residual lesions. By 24 months, 54% of the patients demonstrated complete resolution of their tuberculomas. Although the number of tuberculomas, corticosteroid administration, prior treatment with ATT, and the duration of symptoms before presentation (<6 mo versus >6 mo) did not influence the rate of resolution, larger tuberculomas (maximal size, >4 cm) were observed to resolve more slowly than smaller tuberculomas (<4 cm) (P = 0.02).
More than two-thirds of patients with partially excised or biopsied intracranial tuberculomas exhibited persistent lesions on computed tomographic scans, even after 18 months of ATT. Therefore, the duration of ATT for patients with intracranial tuberculomas should be based on the radiological responses of the tuberculomas. Our data suggest that some patients with intracranial tuberculomas might require prolonged periods of ATT.
本研究旨在确定接受抗结核治疗(ATT)的经组织病理学证实的结核瘤的放射学消退率。还研究了结核瘤大小、结核瘤数量以及加用皮质类固醇治疗对结核瘤消退率的影响。
对28例经组织学证实为颅内结核瘤的患者(年龄范围5 - 48岁;男性14例,女性14例)进行前瞻性对比增强计算机断层扫描监测。患者接受由利福平和异烟肼组成的抗结核治疗18个月,乙胺丁醇和/或吡嗪酰胺至少使用3个月。15例患者还接受了1至6周的皮质类固醇治疗。28例患者中,17例患者的结核瘤接受了部分切除,6例接受了开放性活检,5例接受了立体定向活检。
Kaplan - Meier分析显示,抗结核治疗9个月后,仅18.2%的患者结核瘤完全消退;即使抗结核治疗18个月后,仍有69.2%的患者有残留病灶。到24个月时,54%的患者结核瘤完全消退。虽然结核瘤数量、皮质类固醇给药、既往抗结核治疗情况以及出现症状前的持续时间(<6个月与>6个月)不影响消退率,但观察到较大的结核瘤(最大直径>4 cm)比较小的结核瘤(<4 cm)消退更慢(P = 0.02)。
即使经过18个月的抗结核治疗,超过三分之二接受部分切除或活检的颅内结核瘤患者在计算机断层扫描上仍显示有持续性病灶。因此,颅内结核瘤患者的抗结核治疗疗程应基于结核瘤的放射学反应。我们的数据表明,一些颅内结核瘤患者可能需要延长抗结核治疗时间。